Dyne Therapeutics Investor Relations Material

Dyne Therapeutics Inc. is a biotechnology firm engaged in the development of innovative therapeutics aimed at addressing genetically driven muscle diseases. Established in 2017 and based in Waltham, Massachusetts, the company primarily focuses on advancing a portfolio of muscle disease therapeutics. These efforts include targeting conditions such as myotonic dystrophy type 1, duchenne muscular dystrophy, facioscapulohumeral dystrophy, and other rare skeletal, cardiac, and metabolic muscle diseases. Dyne Therapeutics utilizes its proprietary FORCE platform, which is designed to enhance the delivery of disease-modifying therapeutics directly to muscle tissue. Its shares are listed on the Nasdaq.